Grundinformationen
- Standard-SMILES
COc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1- InChIKey
JEYWNNAZDLFBFF-UHFFFAOYSA-N- Summenformel
- C29H31NO2
- Durchschnittliche Molmasse
- 425,6 g/mol
- Monoisotopische Masse
- 425,23547923
Überblick
Nafoxidine is a member of benzenes, a member of naphthalenes and a ring assembly.
Namen und Bezeichner
- Bevorzugter Name
- Nafoxidine
- IUPAC
- 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine
- Englischer Name
- Nafoxidine
- Summenformel
- C29H31NO2
- Molmasse
- 425.56
Namen und Synonyme
Weitere Namen anzeigen
Datenbank-Bezeichner
- CAS
1845-11-0- PubChem CID
- 4416
- DTXSID
DTXSID7022386- ChEMBL
CHEMBL28211- ChEBI
CHEBI:34881- UNII
- 4RIY10WM82
- EC Number
- 694-510-6
- Nikkaji
- J7.793C
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 5,8
- Polarare Oberfläche (TPSA)
- 21,7 Ų
- H-Brücken-Donoren
- 0
- H-Brücken-Akzeptoren
- 3
- Frei drehbare Bindungen
- 7
- Schwere Atome
- 32
- Formalladung
- 0
- Komplexität
- 611
Experimentelle und physikochemische Eigenschaften
Physikochemische Eigenschaften
- Siedepunkt
- 541.28 °C · 541.28°C (rough estimate)
- Dichte
- 1.099 · 1.0990 (rough estimate)
- Brechungsindex
- 1.629 · 1.6290 (estimate)
- pka
- 9.63 · 9.63±0.20(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to off-white
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Warning
H351 (100%): Suspected of causing cancer [Warning Carcinogenicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Sicherheitsdaten
- Alarmwort
- Warnung
- Gefahrenhinweise
- Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H351
Chemie und Industrie
Pharmakologische Informationen
MeSH Pharmacological Classification
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Anwendungen
VerwendenAnti-estrogen.
Anbieter25 Anbieter
Zugehörige Reaktionen
Verknüpfte Notizen
Wird geladen…